Core Viewpoint - The company has approved the use of idle self-owned funds amounting to 50 million RMB to purchase financial products, aiming to enhance the efficiency of fund utilization while ensuring operational needs and fund safety [1][4]. Group 1: Investment Details - The company signed a contract with Founder Zhongqi Futures Co., Ltd. for the "Founder Zhongqi Xin'an No. 1 Collective Asset Management Plan" with a principal amount of 50 million RMB [1]. - The expected annualized return on the investment is 3.60% [1]. - The investment will focus on fixed-income products, including bank deposits, cash, money market funds, and various types of bonds [1]. Group 2: Risk Management - The finance department will monitor financial market changes and assess potential adverse impacts on the investment products [4]. - The internal audit department will track the investment direction and may conduct audits on the use and custody of the invested funds [4]. - Independent directors and the supervisory board have the authority to conduct regular or ad-hoc checks on the investment products [4]. Group 3: Impact on Operations - The investment of 50 million RMB in financial products will not adversely affect the company's operational needs and is expected to improve the efficiency and return of idle funds, thereby enhancing overall performance and safeguarding shareholder interests [5].

Core Insights - Yisheng Pharmaceutical, established in June 1997 and listed on the Shenzhen Stock Exchange in March 2011, is a well-known Chinese traditional medicine company with strong technical accumulation and market advantages in R&D, production, and sales of traditional Chinese medicine [1] Group 1: Financial Performance - In Q3 2025, Yisheng Pharmaceutical achieved a revenue of 476 million yuan, ranking 56th among 69 companies in the industry, with the industry leader Baiyunshan generating 61.606 billion yuan and the average revenue being 3.755 billion yuan [2] - The net profit for the same period was 24.4188 million yuan, placing the company 49th in the industry, while the top performer, Yunnan Baiyao, reported a net profit of 4.789 billion yuan, with the industry average at 447 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Yisheng Pharmaceutical's debt-to-asset ratio was 22.08%, down from 22.92% year-on-year, which is lower than the industry average of 32.81% [3] - The gross profit margin for Q3 2025 was 75.11%, slightly up from 74.80% year-on-year, and significantly higher than the industry average of 52.44% [3] Group 3: Executive Compensation - The chairman, Zhang Yisheng, received a salary of 1.05 million yuan in 2024, unchanged from 2023, while the general manager, Xue Xiaomin, earned 716,000 yuan, a slight decrease from 717,400 yuan in 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.71% to 19,600, while the average number of circulating A-shares held per shareholder increased by 0.72% to 11,800 [5] - Among the top ten circulating shareholders, Nuoan Multi-Strategy Mixed A (320016) became the eighth largest shareholder with 1.9863 million shares [5]

证券代码：002566 证券简称：益盛药业 公告编号：2025-049 吉林省集安益盛药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省集安益盛药业股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日召开第九届董事会第三次会议、第九届监事会第三次会议，审议通过了《关于 使用闲置自有资金购买理财产品的议案》，为提高公司资金使用效率，合理利用 闲置自有资金，在保证日常经营资金需求和资金安全的前提下，公司使用不超过 5,000 万元人民币的闲置自有资金购买理财产品。内容详见公司于 2025 年 10 月 27 日在指定信息披露媒体及巨潮资讯网（www.cninfo.com.cn）披露的《关于使 用闲置自有资金购买理财产品的公告》（公告编号 2025-047）。 根据上述决议，公司使用 5,000 万元人民币闲置自有资金购买了方正中期期 货有限公司理财产品，现将具体情况公告如下： 一、本次使用闲置自有资金购买理财产品的基本情况 公司与方正中期期货有限公司签署了《方正中期欣安 1 号集合资 ...

Core Viewpoint - The company has conducted its third quarterly board meeting and approved several key resolutions, including the financial report and the use of idle funds for investment in financial products [8][31][37]. Financial Data - The third quarter financial report has not been audited [7]. - The company plans to apply for a total of 5.7 billion yuan in loans from various banks to support its operational needs [9]. Shareholder Information - The company is addressing issues related to shareholding transparency, particularly concerning the shareholding of Liu Jianming, which is still under a holding arrangement [5]. - The company has developed a rectification plan to resolve the issues of shareholding representation and ensure accurate information disclosure [4]. Governance Changes - The board has approved the cancellation of the supervisory board and amendments to the company’s articles of association, which will be submitted for approval at the upcoming shareholder meeting [10][32]. - Various governance documents and rules have been revised and approved by the board, including those related to shareholder meetings and board operations [12][15][19]. Investment Strategy - The company intends to use up to 50 million yuan of idle funds to purchase financial products, aiming to enhance the efficiency of fund utilization while ensuring operational needs are met [37][43]. - The investment will focus on low-risk, high-liquidity financial products issued by banks and asset management companies [38].

Core Viewpoint - Jilin Province Jichang Yisheng Pharmaceutical Co., Ltd. has decided to abolish its supervisory board and amend its articles of association, with the supervisory board's functions being transferred to the audit committee of the board of directors [1][2]. Group 1: Cancellation of Supervisory Board - The company will no longer have a supervisory board, and its powers will be assumed by the audit committee of the board of directors [1]. - The cancellation of the supervisory board requires approval from the shareholders' meeting, and until then, the current supervisory board will continue to fulfill its duties [2]. - The company expresses gratitude to the current supervisors for their contributions during their tenure [2]. Group 2: Amendments to Articles of Association - The company plans to amend certain provisions of its articles of association in light of the cancellation of the supervisory board [2][3]. - The amendments will be subject to approval by the shareholders' meeting and require a special resolution with at least two-thirds of the voting rights present [2][3]. - The final content of the amendments will be subject to approval by the market supervision administration [2][3]. Group 3: Revision and Formulation of Governance Systems - The company is revising and formulating several governance systems to align with the latest legal and regulatory requirements [3][4]. - Revised documents include the articles of association, rules for shareholder meetings, rules for board meetings, and newly established remuneration management systems for directors and senior management [3][4]. - The revised governance documents will also require approval from the shareholders' meeting before they take effect [4].

Core Points - The company has ensured that the information disclosed is true, accurate, and complete, with no false records or misleading statements [1][2][31] - The third-quarter financial report has not been audited [3][7] - The company plans to apply for a total of 5.7 billion yuan in working capital loans from various banks to purchase raw materials and meet operational needs [9][10] Financial Data - The company has confirmed that there are no adjustments or restatements required for previous accounting data [3] - The third-quarter report was approved unanimously by the board of directors [8][31] - The company will use up to 50 million yuan of idle funds to purchase financial products to improve fund utilization efficiency [37][44] Shareholder Information - The company is addressing issues related to shareholding representation and has implemented a rectification plan to clarify actual shareholding situations [4][5] - The company will hold its first extraordinary general meeting of 2025 on November 12, 2025, to discuss various proposals [47][48] Governance Changes - The board has approved the cancellation of the supervisory board and amendments to the company's articles of association [10][32] - Several governance documents have been revised and approved, including rules for shareholder meetings and board meetings [12][15][19]

Core Viewpoint - Jilin Province Jichang Yisheng Pharmaceutical Co., Ltd. has decided to abolish its supervisory board and amend its articles of association, with the supervisory board's functions being transferred to the audit committee of the board of directors [1][2]. Group 1: Cancellation of Supervisory Board - The company will no longer have a supervisory board, and the powers of the supervisory board will be exercised by the audit committee of the board of directors [1]. - Following the cancellation, the supervisors will automatically resign, and related rules such as the "Supervisory Meeting Rules" will be abolished [1]. - The board of directors will seek authorization from the shareholders' meeting to handle the necessary registration and filing for the cancellation of the supervisory board and the amendments to the articles of association [1]. Group 2: Amendments to Articles of Association - The company plans to amend certain provisions of its articles of association in light of the cancellation of the supervisory board [2]. - The amendments will comply with relevant laws and regulations, including the Company Law of the People's Republic of China and the Shenzhen Stock Exchange Listing Rules [2].

Core Insights - Yisheng Pharmaceutical (002566.SZ) reported a revenue of 476 million yuan for the first three quarters of 2025, representing a year-on-year decline of 5.81% [1] - The company's net profit attributable to shareholders was 24.13 million yuan, down 32.72% year-on-year [1] - The non-recurring net profit was 12.56 million yuan, reflecting a year-on-year decrease of 37.81% [1] - Basic earnings per share stood at 0.0729 yuan [1]

Group 1 - Yisheng Pharmaceutical announced plans to use up to 50 million RMB of idle funds to purchase financial products to improve capital efficiency while ensuring operational needs and fund safety [1] - The funds can be used on a rolling basis within a maximum period of 12 months [1] - As of the report date, Yisheng Pharmaceutical has a market capitalization of 2.7 billion RMB [1] Group 2 - For the first half of 2025, Yisheng Pharmaceutical's revenue composition is as follows: 81.06% from the pharmaceutical industry, 10.27% from health products and others, 7.39% from cosmetics, and 1.28% from other sources [1]

Group 1 - Yisheng Pharmaceutical (SZ 002566) announced on October 26 that its ninth board meeting was held on October 24, 2025, to review proposals regarding the revision and formulation of certain governance systems [1] - For the first half of 2025, Yisheng Pharmaceutical's revenue composition was as follows: 81.06% from the pharmaceutical industry, 10.27% from health products and others, 7.39% from cosmetics, and 1.28% from other sources [1] - As of the report date, Yisheng Pharmaceutical's market capitalization was 2.7 billion yuan [1]